Positive Health Online
Your Country
![[Image: http://www.abundanceandhealth.co.uk]](/img/original/BannerAvatar/2836.df7d2315253110ff5b3a566f94871f99.jpg "http://www.abundanceandhealth.co.uk")
![[Image: https://www.water-for-health.co.uk/]](/img/original/BannerAvatar/4046.12831f50177f8848ee87b8e94411d6b3.jpg "https://www.water-for-health.co.uk/")
![[Image: http://www.balens.co.uk]](/img/original/BannerAvatar/2148.50367fa908013fae0a7f1a171543ef92.jpg "http://www.balens.co.uk")
![[Image: http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer]](/img/original/BannerAvatar/1859.1296090fd8385e7ceff51c8011559097.jpg "http://www.drsgoodman.com/books-goodman/52-nutrition-and-cancer")
Research: TAYEBI-KHOSROSHAHI and COLLEAGUES,
Listed in Issue 236
Abstract
TAYEBI-KHOSROSHAHI and COLLEAGUES, (1)Chronic Kidney Disease Research Center, Imam Reza Hospital and Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. farid.panahi@gmail.com evaluated the effect of omega-3 supplementation on serum homocysteine level in patients on haemodialysis.
Background
Patients with end-stage renal disease are at a high risk of adverse cardiovascular events. Elevated level of homocysteine is an important risk factor for cardiovascular morbidity and mortality in dialysis patients. There are some strategies for reduction of serum homocysteine level in these patients, including folate and vitamin supplementation. The aim of the present study was to evaluate the effect of omega-3 supplementation on serum homocysteine level in patients on haemodialysis.
Methodology
In a randomized controlled trial, 100 haemodialysis patients were assigned into two groups to receive omega-3 (oral capsule, 3 g/d) or placebo for 2 months. Complete blood count, blood urea nitrogen, serum creatinine, serum lipids, and serum homocysteine levels were measured before the study and after 2 months at the end of study.
Results
Of 100 patients, 6 in each group were excluded, and 44 patients in each group completed the study. There were no significant differences regarding the age, sex, and the number of dialysis sessions per week between the two groups. No difference was observed between the two groups in the laboratory investigations at the end of the study, except for a significant reduction in serum homocysteine level in the omega-3 group as compared to the placebo group (P = .03).
Conclusion
Our study showed a significant reduction regulated by omega-3 supplementation in serum homocysteine level which is a cardiovascular risk factor among haemodialysis patients. Omega-3 can be considered as another homocysteine-reducing agent in this population.
References
Tayebi-Khosroshahi H(1), Dehgan R, Habibi Asl B, Safaian A, Panahi F, Estakhri R, Purasgar B. Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients. Iran J Kidney Dis. 7(6):479-84. Nov 2013. Comment in Iran J Kidney Dis. 7(6):421-2. Nov 2013.
Comment
The above research out of Iran documents the significant reduction in haemodialysis patients of serum homocysteine levels, regulated by omega-3 supplementation, a cardiovascular risk factor among these patients.
